Scilex Holding Company (NASDAQ: SCLX)
$1.96
+0.0700 ( +3.70% ) 778.5K
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Market Data
Open
$1.96
Previous close
$1.89
Volume
778.5K
Market cap
$237.40M
Day range
$1.85 - $2.02
52 week range
$0.73 - $6.55
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Sep 25, 2023 |
8-k | 8K-related | 14 | Sep 22, 2023 |
8-k | 8K-related | 14 | Sep 21, 2023 |
8-k | 8K-related | 17 | Sep 13, 2023 |
8-k | 8K-related | 15 | Sep 11, 2023 |
8-k | 8K-related | 13 | Sep 08, 2023 |
8-k | 8K-related | 13 | Aug 31, 2023 |
10-q | Quarterly Reports | 80 | Aug 11, 2023 |
8-k | 8K-related | 15 | Jul 07, 2023 |
8-k | 8K-related | 13 | Jul 05, 2023 |